129 related articles for article (PubMed ID: 10172484)
21. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Chevallier B; Chollet P; Merrouche Y; Roche H; Fumoleau P; Kerbrat P; Genot JY; Fargeot P; Olivier JP; Fizames C
J Clin Oncol; 1995 Jul; 13(7):1564-71. PubMed ID: 7541448
[TBL] [Abstract][Full Text] [Related]
22. [A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Oyama A; Ota K; Asano S; Takaku F; Yoshida Y; Uzuka Y; Omine M; Furusawa S; Takatani O; Sawada U
Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2533-48. PubMed ID: 1702132
[TBL] [Abstract][Full Text] [Related]
23. Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.
Drummond M; Menzin J; Oster G
Pharmacoeconomics; 1994; 6 Suppl 2():18-26. PubMed ID: 10155592
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
[TBL] [Abstract][Full Text] [Related]
25. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
26. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
27. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
Dunn CJ; Goa KL
Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
[TBL] [Abstract][Full Text] [Related]
28. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison.
Toner GC; Shapiro JD; Laidlaw CR; Rischin D; Millward MJ; Wolf M; Januszewicz H; Mitchell SV; Curran AC; Matthews JP; Bishop JF
J Clin Oncol; 1998 Dec; 16(12):3874-9. PubMed ID: 9850033
[TBL] [Abstract][Full Text] [Related]
29. A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia.
Juan O; Campos JM; Carañana V; Sanchez JJ; Casañ R; Alberola V
Support Care Cancer; 2001 Jun; 9(4):241-6. PubMed ID: 11430419
[TBL] [Abstract][Full Text] [Related]
30. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Dranitsaris G; Sutcliffe SB
Leuk Lymphoma; 1995 Mar; 17(1-2):139-45. PubMed ID: 7539658
[TBL] [Abstract][Full Text] [Related]
31. Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer.
Kotake T; Usami M; Miki T; Togashi M; Akaza H; Kubota Y; Matsumura Y
Int J Urol; 1999 Feb; 6(2):61-7. PubMed ID: 10226809
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
33. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients.
Dubreuil-Lemaire ML; Gori A; Vittecoq D; Panelatti G; Tharaux F; Palisses R; Gharakhanian S; Rozenbaum W;
Eur J Haematol; 2000 Nov; 65(5):337-43. PubMed ID: 11092465
[TBL] [Abstract][Full Text] [Related]
34. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
[TBL] [Abstract][Full Text] [Related]
36. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of available clinical evidence - filgrastim compared with lenograstim.
Sourgens H; Lefrère F
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):510-8. PubMed ID: 21781651
[TBL] [Abstract][Full Text] [Related]
38. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
39. Which one is more effective, filgrastim or lenograstim, during febrile neutropenia attack in hospitalized patients with solid tumors?
Sonmez OU; Guclu E; Uyeturk U; Esbah O; Turker I; Bal O; Budakoglu B; Arslan UY; Karabay O; Oksuzoglu B
Asian Pac J Cancer Prev; 2015; 16(3):1185-9. PubMed ID: 25735353
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
